87 ± 72.41% (control group) to (314.23 ± 46.32%, 257.18 ± 26.5%, p < 0.01) respectively. The mRNA expressions of DNMT1, DNMT3a and DNMT3b were down-regulated FG-4592 mouse after ADO alone or combination treatment with HCY. The mRNA expressions of lncRNA-MEG3, P53, caspase-3, caspase-9, cytochrome

C were up-regulated and MDM-2 were down-regulated after ADO alone or combination treatment with HCY. Conclusion: ADO alone or combination treatment with HCY can suppress DNMTs and decreased cellular methylation metabolism. The effects of demethylation may activate lncRNA MEG3 gene, P53 pathway and the mitochondrial pathway and at last led to cell apoptosis. Key Word(s): 1. adenosine; 2. homocysteine; 3. methylation; 4. hepatocellular carcinoma; 5. apoptosis Presenting Author: I-CHEN WU Additional Authors: MING TSANG WU Corresponding Author: I-CHEN WU Affiliations: Kaohsiung Medical University Hosp Objective: This study aims to identify the novel and potential upregulated genes related to secretionary or membranous proteins for the clinical diagnosis and staging of esophageal squamous cell carcinoma (ESCC). Methods: By combining microarray-based screening, which contained at least 25,000 DNA oligonucleotide probes, of esophageal tumors from both N-nitrosomethylbenzylamine- and arecoline-induced F344 rats and

17 human ESCC specimens, we further confirmed the potential candidate

genes by tissue arrays in 243 cancer tissues and 126 LY2157299 manufacturer normal tissues of esophagus from Taiwan, Korea, and USA and by ELISA in 78 serum specimens of ESCC patients from Taiwan. Results: Four candidate genes, including ATP1A1, SPINT2, CMTM8, and AGR2, were chosen by microarray-based screening of 17 paired tissues from 17 ESCC patients. Only ATP1A1 (ATPase Na+/K+ transporting alpha 1 polypeptide) passed validation by RT-PCR and IHC staining in ESCC tissue specimens. check details We found positive ATP1A1 immunostaining in 207 (85%) of the 243 cancer tissues and 88 (70%) of the 126 normal tissues. After adjustment for age and sex, ATP1A1 overexpression had a 3.2-fold (95% CI = 1.8–5.6) to be likely in cancer tissues than in normal tissues. Using the median level of 1,465.0 pg/mL of serum ATP1A1 protein expression as the cut-off point, we found that patients with stage III-IV had a 2.91-fold (1.12–7.36) likely to have high serum ATP1A1 levels than those with stage I-II after adjustment for age and sex. Conclusion: ATP1A1 overexpression may be a potential noninvasive marker of the clinical diagnosis and staging for ESCC patients. Key Word(s): 1. ATPase Na+/K+ transporting alpha 1 polypeptide; 2. microarray-based screening; 3. N-nitrosomethylbenzylamine; 4. arecoline; 5. F344; 6.